Skip to Main Content

Autoimmune hemolytic anemia (AHA) is characterized by shortened red blood cell (RBC) survival and the presence of autoantibodies directed against autologous RBCs. A positive direct antiglobulin test (DAT, also known as the Coombs test) is essential for diagnosis. Most patients with AHA (80%) exhibit warm-reactive antibodies of the immunoglobulin (Ig) G isotype on their red cells. Most of the remainder of patients exhibit cold-reactive autoantibodies. Two types of cold-reactive autoantibodies to RBCs are recognized: cold agglutinins and cold hemolysins. Cold agglutinins are generally of IgM isotype, whereas cold hemolysins usually are of IgG isotype. The DAT may detect IgG, proteolytic fragments of complement (mainly C3), or both on the RBCs of patients with warm-antibody AHA. In cold-antibody AHA, only complement is detected because the antibody dissociates from the RBCs during washing of the cells. About half of patients with AHA have no underlying associated disease; these cases are termed primary or idiopathic. Secondary cases are associated with underlying autoimmune, malignant, or infectious diseases or with ingestion of certain drugs.

Although most patients do not require transfusion of RBCs, transfusion should not be withheld from those with symptomatic anemia. In warm-antibody AHA, glucocorticoids are effective in slowing the rate of hemolysis. Splenectomy is indicated for patients who require an unacceptably high maintenance dose or prolonged administration of glucocorticoids. Intravenous immunoglobulin may provide short-term control of hemolysis. Immunosuppressive drugs and danazol have been used successfully in refractory cases. In cold agglutinin- and cold hemolysin-mediated hemolysis, keeping the patient warm and treating underlying lymphoproliferative disorders usually are effective. Rituximab has been effective in reported cases of both warm and cold AHA. Drug-immune hemolytic anemia usually is ameliorated by discontinuation of the offending drug.

Acronyms and Abbreviations

Acronyms and abbreviations that appear in this chapter include: AHA, autoimmune hemolytic anemia; CLL, chronic lymphocytic leukemia; DAF, decay accelerating factor; DAT, direct antiglobulin test; HLA, human leukocyte antigen; HRF, homologous restriction factor; HS, hereditary spherocytosis; IAT, indirect antiglobulin test; Ig, immunoglobulin; IGHV, immunoglobulin heavy chain variable region; PNH, paroxysmal nocturnal hemoglobinuria; RBC, red blood cell; SLE, systemic lupus erythematosus.

The two main features of immune red blood cell (RBC) injury are (1) shortened RBC survival in vivo and (2) evidence of host antibodies reactive with autologous RBCs, most frequently demonstrated by a positive direct antiglobulin test (DAT), also known as the Coombs test. Most cases in adults are mediated by warm-reactive autoantibodies. A smaller proportion of patients exhibit cold-reactive autoantibodies or drug-related antibodies.

By the early 20th century, reticulocytes, spherocytes, and osmotic fragility of RBCs had been described. Clinicians could diagnose hemolytic anemia, but the distinction between congenital and acquired forms was imprecise. Some clinicians even doubted the existence of acquired hemolytic anemia.1 The sera of some patients with hemolytic anemia directly agglutinated saline suspensions of normal or autologous human RBCs. These serum factors, later shown to be specific antibodies (largely of the immunoglobulin ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.